BeOne Medicines (BEIGF) Short-term Investments (2015 - 2023)

BeOne Medicines (BEIGF) has reported Short-term Investments for 9 consecutive years, with $2.6 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Short-term Investments fell 99.61% year-over-year to $2.6 million in Q4 2023; TTM through Dec 2023 was $2.6 million, a 99.61% decrease from a year earlier, with the FY2023 full-year figure at $2.6 million, down 99.61% from the prior year.
• Short-term Investments was $2.6 million for Q4 2023 at BeOne Medicines, down from $107.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $3.3 billion in Q4 2020 and troughed at $2.6 million in Q4 2023.
• A 5-year average of $1.4 billion and a median of $1.0 billion in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 796.21% in 2020 and plunged 99.61% in 2023, its largest moves.
• Over 5 years, Short-term Investments stood at $364.7 million in 2019, then surged by 796.21% to $3.3 billion in 2020, then sank by 31.41% to $2.2 billion in 2021, then tumbled by 70.33% to $665.3 million in 2022, then sank by 99.61% to $2.6 million in 2023.
• The last three Short-term Investments figures came in at $2.6 million (Q4 2023), $107.0 million (Q3 2023), and $105.7 million (Q2 2023), per Business Quant data.